目次
Table of Content
1. Tumor Infiltrating Lymphocytes (TIL): A Brief Introduction
1.1 Overview
1.2 TIL History and Concept
2. Emergence Of Tumor Infiltrating Lymphocytes Therapy
2.1 Tumor Infiltrating Lymphocytes As Prognostic Biomarkers
2.2 Tumor Infiltrating Lymphocytes Therapy Combinational Approach
3. Amtagvi - First Approved Tumor Infiltrating Lymphocyte Therapy
3.1 Overview and Patent Insight
3.2 Dosage and Price Analysis
3.3 Sales Analysis
4. Global Tumor Infiltrating Lymphocytes Therapy Market Overview
4.1 Current Market Scenario
4.2 Future Opportunities
5. Tumor Infiltrating Lymphocytes Therapy Development Trends By Region
5.1 US
5.2 Canada
5.3 China
5.4 UK
5.5 EU
6. Tumor Infiltrating Lymphocytes Therapy Approaches By Cancer
6.1 Melanoma
6.2 Lung Cancer
6.3 Breast Cancer
6.4 Gastrointestinal Cancers (Colorectal Cancer, Gastric Cancer, Pancreatic
Cancer, Hepatocellular Carcinoma)
6.5 Gynecological Cancers (Ovarian Cancer, Uterine/ Endometrial Cancer,
Cervical Cancer)
6.6 Genitourinary Cancers (Bladder/Urothelial Carcinoma, Renal Cell, Prostate
Cancer)
6.7 Head and Neck Cancers
6.8 Brain Cancers
7. Global Tumor Infiltrating Lymphocytes Therapy Market Dynamics
7.1 Market Drivers and Opportunities
7.2 Market Challenges and Restraints
8. Global Tumor Infiltrating Lymphocytes Therapy Trials Overview
8.1 By Breakthrough and Fast Track Status
8.2 By Country
8.3 By Company
8.4 By Indication
8.5 By Phase
8.6 By Orphan Status
9. Global Tumor Infiltrating Lymphocyte Therapies Clinical Trials By Company, Indication and Phase
9.1 Research
9.2 Preclinical
9.3 Phase-0
9.4 Phase-I
9.5 Phase-I/II
9.6 Phase-II
9.7 Phase-III
10. Marketed Tumor Infiltrating Lymphocyte Therapies Clinical Pipeline By Company, Indication and Phase
11. Tumor Infiltrating Lymphocytes Therapy Proprietary Technologies Insight By Companies
12. Competitive Landscape
12.1 Adaptimmune
12.2 AgonOx
12.3 GRIT Biotechnology
12.4 ImmuneCyte
12.5 Intima Bioscience
12.6 Iovance Biotherapeutics
12.7 Juncell Therapeutics
12.8 Leman Biotech
12.9 Obsidian Therapeutics
12.10 RootPath
List of Figures & Tables
Figure 1-1: Procedure Of Tumor Infiltrating Lymphocytes Therapy
Figure 1-2: Phenotypic Composition of TILs
Figure 1-3: Components Of Rapid Expansion Protocol
Figure 1-4: Historical Evolution Of TIL Therapy
Figure 2-1: Advantages Of TIL Therapy
Figure 2-2: TILs As Biomarkers
Figure 2-3: Combination Strategies To Boost TIL Therapy
Figure 3-1: Amtagvi - Approval Year by Region
Figure 3-2: Amtagvi - US Patent/Application Information
Figure 3-3: Amtagvi - Global Annual Sales (US$ Million), 2024-2025
Figure 3-4: Amtagvi - Global Quarterly Sales (US$ Million), Q1 and Q2’2025
Figure 3-5: Amtagvi - Global Quarterly Sales (US$ Million), Q2-Q4’2024
Figure 4-1: Global - Tumor Infiltrating Lymphocytes Therapy Market (US$ Million), 2024 and 2025
Figure 4-2: Global Tumor Infiltrating Lymphocyte Therapy Market - Future Opportunities
Figure 4-3: Global - Tumor Infiltrating Lymphocytes Therapy Market (US$ Million), 2029 - 2030
Figure 6-1: NCI-2022-06873 Phase I (NCT05470283) Study - Initiation and Estimated Completion Year
Figure 6-2: NCI-2022-06873 Phase I (NCT05470283) Study - Initiation and Estimated Completion Year
Figure 6-3: MM2319 Phase I (NCT06204991) Study - Initiation and Estimated Completion Year
Figure 6-4: TILVANCE-301 Phase III (NCT05727904) Study - Initiation and Estimated Completion Year
Figure 6-5: BaseTIL-03M Phase I (NCT05869539) Study - Initiation and Estimated Completion Year
Figure 6-6: NCI-2012-01368 Phase II (NCT00338377) Study - Initiation and Estimated Completion Year
Figure 6-7: MCC-21971 Phase I (NCT05681780) Study - Initiation and Estimated Completion Year
Figure 6-8: 14-C-0104 Phase II (NCT02133196) Study - Initiation and Estimated Completion Year
Figure 6-9: IOV-COM-202 Phase II (NCT03645928) Study - Initiation and Estimated Completion Year
Figure 6-10: IOV-LUN-202 Phase II (NCT04614103) Study - Initiation and Estimated Completion Year
Figure 6-11: IOV-GM1-201 Phase I/II (NCT05361174) Study - Initiation and Estimated Completion Year
Figure 6-12: CCI-2005 Phase I (NCT05676749) Study - Initiation and Estimated Completion Year
Figure 6-13: MCC-21971 Phase I (NCT05681780) Study - Initiation and Estimated Completion Year
Figure 6-14: CheckCell-2 Phase I/II (NCT05566223) Study - Initiation and Estimated Completion Year
Figure 6-15: TIL-2021001 Phase I (NCT05366478) Study - Initiation and Estimated Completion Year
Figure 6-16: ITIL-306-201 Phase I (NCT05397093) Study - Initiation and Estimated Completion Year
Figure 6-17: 14-C-0104 Phase II (NCT02133196) Study - Initiation and Estimated Completion Year
Figure 6-18: TILS001 Phase I/II (NCT05451784) Study - Initiation and Estimated Completion Year
Figure 6-19: GC101-21K177 Phase I (NCT05142475) Study - Initiation and Estimated Completion Year
Figure 6-20: Phase I (NCT05505812) Study - Initiation and Estimated Completion Year
Figure 6-21: ZZTIL-012 Phase I (NCT04842812) Study - Initiation and Estimated Completion Year
Figure 6-22: 10-C-0166 Phase II (NCT01174121) Study - Initiation and Estimated Completion Year
Figure 6-23: 2019LS002 Phase I (NCT04426669) Study - Initiation and Estimated Completion Year
Figure 6-24: NCI-2024-07763 Phase I/II (NCT06598371) Study - Initiation and Estimated Completion Year
Figure 6-25: Phase I (NCT04766320) Study - Initiation and Estimated Completion Year
Figure 6-26: GC203-1.0 Phase II (NCT05468307) Study - Initiation and Estimated Completion Year
Figure 6-27: GC201-1.0 Phase I (NCT05098171) Study - Initiation and Estimated Completion Year
Figure 6-28: 10-C-0166 Phase II (NCT01174121) Study - Initiation and Estimated Completion Year
Figure 6-29: NCI-2018-00918 Phase II (NCT03449108) Study - Initiation and Estimated Completion Year
Figure 6-30: XHKT-SCT006-2022 Phase II (NCT05342506) Study - Initiation and Estimated Completion Year
Figure 6-31: TIL-2021001 Phase I (NCT05366478) Study - Initiation and Estimated Completion Year
Figure 6-32: C-145-04 Phase II (NCT03108495) Study - Initiation and Estimated Completion Year
Figure 6-33: NCI-2024-08121 Phase II (NCT06626256) Study - Initiation and Estimated Completion Year
Figure 6-34: MCC-21894 Phase I (NCT05768347) Study - Initiation and Estimated Completion Year
Figure 6-35: ITIL-306-201 Phase I (NCT05397093) Study - Initiation and Estimated Completion Year
Figure 6-36: IOV-COM-202 Phase II (NCT03645928) Study - Initiation and Estimated Completion Year
Figure 6-37: NCI-2018-00918 Phase II (NCT03449108) Study - Initiation and Estimated Completion Year
Figure 6-38: GC101-JD-LK Phase I (NCT04943913) Study - Initiation and Estimated Completion Year
Figure 6-39: BAH2472 Phase I/II (NCT06626256) Study - Initiation and Estimated Completion Year
Figure 7-1: Global Tumor Infiltrating Lymphocyte Therapy Market - Drivers and Opportunities
Figure 7-2: Global Tumor Infiltrating Lymphocyte Therapy Market - Challenges and Strategic Solutions
Figure 8-1: Global - Tumor Infiltrating Lymphocytes Therapy In Clinical Trials By Priority Status, 2025 Till 2030
Figure 8-2: Global - Tumor Infiltrating Lymphocytes Therapy In Clinical Trials By Country, 2025 Till 2030
Figure 8-3: Global - Tumor Infiltrating Lymphocytes Therapy In Clinical Trials By Company, 2025 Till 2030
Figure 8-4: Global - Tumor Infiltrating Lymphocytes Therapy In Clinical Trials By Indication, 2025 Till 2030
Figure 8-5: Global - Tumor Infiltrating Lymphocytes Therapy In Clinical Trials By Phase, 2025 Till 2030
Figure 8-6: Global - Tumor Infiltrating Lymphocytes Therapy In Clinical Trials By Orphan Status, 2025 Till 2030
Figure 11-1: Iovance Biotherapeutics - TIL Therapy Platform
Figure 11-2: Iovance Biotherapeutics - Streamlined 22-day GMP Manufacturing Process
Figure 11-3: Obsidian Therapeutics - cytoDRiVE Platform
Figure 11-4: Novoleucel Steps Involved
Table 1-1: TIL Therapy vs Conventional Therapies
Table 1-2: TIL Presence In Different Cancers
Table 1-3: Improvements Over Time In TIL Manufacturing
Table 1-4: TIL Manufacturing Process - Traditional and Modern TIL Production Protocols
Table 2-1: TIL Therapy vs CAR-T Therapy
Table 2-2: Key Prognostic TIL Subtypes and Their Functions
Table 2-3: Tumor Microenvironment Transformation By Combination Therapy
Table 2-4: Combinational Approaches In TILs For Different Cancer Indications
Table 3-1: Global Regulatory Status Of Amtagvi